BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi JI. Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes. Transl Lung Cancer Res 2019;8:32-47. [PMID: 30788233 DOI: 10.21037/tlcr.2018.06.11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Arruda GV, Lourenção M, de Oliveira JHC, Galendi JSC, Jacinto AA. Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system. The Lancet Regional Health - Americas 2022;14:100329. [DOI: 10.1016/j.lana.2022.100329] [Reference Citation Analysis]
2 Ocolotobiche EE, Banegas YC, Ferraris G, Martínez M, Güerci AM. Cellular bases of hypofractionated radiotherapy protocols for lung cancer. An Acad Bras Cienc 2022;94:e20210056. [PMID: 35894359 DOI: 10.1590/0001-3765202220210056] [Reference Citation Analysis]
3 Goizueta AA, Casal RF. Bronchoscopic Lung Nodule Ablation. Curr Pulmonol Rep. [DOI: 10.1007/s13665-022-00287-5] [Reference Citation Analysis]
4 Jacobs CD, Mehta K, Gao J, Wang X, Salama JK, Kelsey CR, Torok JA. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. Clin Lung Cancer 2021:S1525-7304(21)00159-5. [PMID: 34301453 DOI: 10.1016/j.cllc.2021.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kotha NV, Cherry DR, Bryant AK, Nalawade V, Stewart TF, Rose BS. Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point. Clin Transl Radiat Oncol 2021;28:133-40. [PMID: 33997320 DOI: 10.1016/j.ctro.2021.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ma M, Ren W, Li M, Niu C, Dai J. Dosimetric comparison of coplanar and noncoplanar beam arrangements for radiotherapy of patients with lung cancer: A meta-analysis. J Appl Clin Med Phys 2021;22:34-43. [PMID: 33634946 DOI: 10.1002/acm2.13197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rodrigues I, Figueiredo T, Gagean J, Ferreira C, Laranja A, Ramos T, Conde S, Moreira D, Cardia J. Prognostic factors and clinical outcomes after stereotactic radiotherapy for primary lung tumors. Rep Pract Oncol Radiother 2020;25:943-50. [PMID: 33093813 DOI: 10.1016/j.rpor.2020.09.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Jia Z, Wang Y, Cao L, Wang Y, Song Y, Yang X, Bing Z, Cao Z, Liu P, Zhang S, Chen Z, Huang M, Yu Y, Han-Zhang H, Song J, Christoph DC, Passaro A, Gridelli C, Hishida T, Liang N, Li S. First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. J Thorac Dis 2020;12:3764-73. [PMID: 32802455 DOI: 10.21037/jtd-20-1882] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Giaj-Levra N, Borghetti P, Bruni A, Ciammella P, Cuccia F, Fozza A, Franceschini D, Scotti V, Vagge S, Alongi F. Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Rev Anticancer Ther 2020;20:387-402. [PMID: 32321330 DOI: 10.1080/14737140.2020.1760094] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
10 Pang C, Zhang X, Huang M, Xie G, Liu S, Ye X, Zhang X. Dendrobium officinalis inhibited tumor growth in non-small cell lung cancer. Transl Cancer Res 2020;9:2683-91. [PMID: 35117627 DOI: 10.21037/tcr.2020.02.79] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]